TippingPoint Biosciences: $4.5 Million Raised To Target Epigenetic Drivers In Pediatric Brain Cancer
By Amit Chowdhry ● Apr 1, 2026
TippingPoint Biosciences has raised $4.5 million in an oversubscribed seed funding round to advance a novel drug discovery platform focused on previously “undruggable” epigenetic targets. The financing was led by SOSV and LKS Fund, with participation from Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer Society BrightEdge, XEIA, and WeCAN.